Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorKarta, Jessica
dc.contributor.authorMeyers, Marianne
dc.contributor.authorRodriguez, Fabien
dc.contributor.authorKoncina, Eric
dc.contributor.authorGilson, Cédric
dc.contributor.authorKlein, Eliane
dc.contributor.authorAlonso Landeira, Lidia
dc.contributor.authorAguilera Pujabet, Mònica
dc.contributor.authorNuciforo, Paolo
dc.date.accessioned2025-10-30T12:18:24Z
dc.date.available2025-10-30T12:18:24Z
dc.date.issued2025-10
dc.identifier.citationKarta J, Meyers M, Rodriguez F, Koncina E, Gilson C, Klein E, et al. Fusobacterium nucleatum interacts with cancer-associated fibroblasts to promote colorectal cancer. EMBO J. 2025 Oct;44(19):5375–93.
dc.identifier.issn1460-2075
dc.identifier.urihttp://hdl.handle.net/11351/13983
dc.descriptionFusobacterium nucleatum; Cancer-associated fibroblasts; Colorectal Cancer
dc.description.abstractGut microbial species contribute to colorectal cancer (CRC) by interacting with tumor or immune cells, however if CRC-associated bacteria engage with stromal components of the tumor microenvironment remains unclear. Here, we report interaction between the CRC-associated bacterium Fusobacterium nucleatum and cancer-associated fibroblasts (CAFs), and show that F. nucleatum is present in the stromal compartment in murine CRC models in vivo and can attach to and invade CAFs. F. nucleatum-exposed CAFs exhibit a pronounced inflammatory-CAF (iCAF) phenotype, marked by elevated expression of established iCAF markers, secretion of pro-inflammatory cytokines such as CXCL1, IL-6 and IL-8, generation of reactive oxygen species (ROS), and an increased metabolic activity. In co-culture experiments, the interaction of cancer cells with F. nucleatum-stimulated CAFs enhances invasion, a finding further validated in vivo. Altogether, our results point to a role for the tumor microbiome in CRC progression by remodeling the tumor microenvironment through its influence on cancer-associated fibroblasts, suggesting novel therapeutic strategies for targeting CRC.
dc.language.isoeng
dc.publisherEMBO Press
dc.relation.ispartofseriesThe EMBO Journal;44(19)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectRecte - Càncer
dc.subjectIntestins - Microbiologia
dc.subjectFibroblasts
dc.subjectMalalties bacterianes gramnegatives
dc.subject.meshGastrointestinal Microbiome
dc.subject.meshFusobacterium Infections
dc.subject.meshColorectal Neoplasms
dc.subject.meshCancer-Associated Fibroblasts
dc.titleFusobacterium nucleatum interacts with cancer-associated fibroblasts to promote colorectal cancer
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1038/s44318-025-00542-w
dc.subject.decsmicrobiota intestinal
dc.subject.decsinfecciones por Fusobacterium
dc.subject.decsneoplasias colorrectales
dc.subject.decsfibroblastos asociados al cáncer
dc.relation.publishversionhttps://doi.org/10.1038/s44318-025-00542-w
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Karta J, Meyers M, Rodriguez F, Koncina E, Gilson C, Klein E] Department of Life Sciences and Medicine (DLSM), Faculty of Science, Technology and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg. [Aguilera Pujabet M, Alonso L, Nuciforo PG] Molecular Oncology Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid40846900
dc.identifier.wos001555491700001
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2017-2020/PI20%2F00889
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record